Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

O1139

Sigma-Aldrich

Anti-Osteoprotegerin antibody produced in goat

affinity isolated antibody, lyophilized powder

Sinônimo(s):

Anti-OPG

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

100 μG
R$ 4.072,00

R$ 4.072,00


Em estoqueDetalhes


Solicite uma grande encomenda

Selecione um tamanho

Alterar visualização
100 μG
R$ 4.072,00

About This Item

Número MDL:
Código UNSPSC:
51111800
NACRES:
NA.41

R$ 4.072,00


Em estoqueDetalhes


Solicite uma grande encomenda

fonte biológica

goat

Nível de qualidade

conjugado

unconjugated

forma do anticorpo

affinity isolated antibody

tipo de produto de anticorpo

primary antibodies

clone

polyclonal

Formulário

lyophilized powder

reatividade de espécies

mouse

técnica(s)

immunohistochemistry: 5-15 μg/mL
neutralization: suitable
western blot: 0.1-0.2 μg/mL

nº de adesão UniProt

temperatura de armazenamento

−20°C

modificação pós-traducional do alvo

unmodified

Informações sobre genes

Descrição geral

Osteoprotegerin (OPG) secreted by osteoblasts and osteogenis stromal stem cells belongs to the TNF receptor superfamily. OPG is expressed in bone marrow, osteoblasts, heart, lung, kidney, thymus, B lymphocytes, chondrocytes and smooth muscle cells. The ratio of OPG and receptor activator of NF-κB Ligand (RANKL) is crucial determining the bone mass. Receptor activator of NF-κB (RANK)/RANKL/OPG axis decides the bone biology. OPG binds RANKL and prevents the activation of osteoclasts, the cells that deplete bone mass. Excess levels of OPG lead to osteopetrosis while deficiency results in osteoporosis. The RANK/RANKL/OPG pathway mediates the activation of multiple pathways such as NF-κB, Akt, JNK, and MAPK
Anti-osteoprotegerin specifically reacts with recombinant mouse OPG. The antibody may cross react with human OPG (25% homology).

Especificidade

The antibody has the ability to neutralize the biological activity of recombinant mouse OPG.

Imunogênio

purified recombinant mouse osteoprotegerin expressed in mouse NSO cells.

Aplicação

Anti-osteoprotegerin antibody may be used to neutralize mouse OPG at neutralization dose (ND50) of 0.5-2 μg/ml. The antibody is suitable for immunoblotting at a working concentration of 0.1-0.2 μg/ml.

forma física

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates.

Exoneração de responsabilidade

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Não está encontrando o produto certo?  

Experimente o nosso Ferramenta de seleção de produtos.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 1

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, type N95 (US)


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Brendan F Boyce et al.
Current osteoporosis reports, 5(3), 98-104 (2007-10-11)
Understanding of osteoclast formation and activation has advanced considerably since the discovery of the RANKL/RANK/OPG system in the mid 1990s. Osteoblasts and stromal stem cells express receptor activator of NF-jB ligand (RANKL), which binds to its receptor, RANK, on the
I Silva et al.
Acta reumatologica portuguesa, 36(3), 209-218 (2011-11-25)
The discovery of the receptor activator of nuclear factor-kB (RANK)/RANK Ligand (RANKL)/osteoprotegerin (OPG) pathway contributed to the understanding of how bone formation and resorption were processed and regulated. RANKL and OPG are members of the tumor necrosis factor (TNF) and
Shabber Syed et al.
Journal of cardiovascular development and disease, 9(8) (2022-08-26)
Calcific aortic valve disease (CAVD) is a common cardiac defect, particularly in the aging population. While several risk factors, such as bi-leaflet valve structure and old age, have been identified in CAVD pathogenesis, molecular mechanisms resulting in this condition are
Anne-Priscille Trouvin et al.
Clinical interventions in aging, 5, 345-354 (2011-01-14)
Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway
W C Dougall et al.
Genes & development, 13(18), 2412-2424 (1999-09-29)
The physiological role of the TNF receptor (TNFR) family member, RANK, was investigated by generating RANK-deficient mice. RANK(-/-) mice were characterized by profound osteopetrosis resulting from an apparent block in osteoclast differentiation. RANK expression was not required for the commitment

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica